The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

Acne vulgaris is a common skin problem which can be challenging to treat. Enhancing the
efficacy and tolerability of treatment regimens can enhance compliance and outcomes thereby
potentially decreasing the morbidities associated with acne vulgaris.

The present study is designed to assess the ability of Power of 3 with resveratrol to improve
efficacy and tolerability of an existing combination acne medication.

Inclusion Criteria:

1. Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
of Acne vulgaris

2. On the face, ≥ 20 non-inflammatory lesions (i.e., open and closed comedones) AND < 75
inflammatory lesions (i.e., papules and pustules) AND ≤ 1 nodulocystic lesions (i.e.,
nodules and cysts).

3. Investigator's Global Assessment (IGA) of acne severity grade 2 or 3

4. Subject must be able to follow study instructions and likely to complete all required
visits, as assessed by the Investigator.

5. Subject/Guardian must sign an IRB-approved Informed Consent/Assent/Assent Form
including photography consent, and the Authorization for Use and release of Health and
Research Study Information (HIPAA) form prior to any study-related procedures being
performed

Exclusion Criteria:

1. Presence of any skin condition that would interfere with the diagnosis or assessment
of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
folliculitis, or bacterial folliculitis).

2. Subjects who have acne conglobata, acne fulminans and secondary acne (e.g.:

chloracne and drug induced acne).

3. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere
with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.

4. History of hypersensitivity or allergy to benzoyl peroxide or adapalene and or any of
the study product ingredients.

5. Subjects who have a severe or intense irritation on the face.

6. Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g.
Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day
(multivitamins are allowed).

7. Use for less than 3 months prior to baseline (Randomization) of estrogens or oral
contraceptives; use of such therapy is allowed if it will remain constant throughout
the study.

8. Use on the face within 1 month prior to baseline (Randomization) or during the study
of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy,
4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.

9. Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2)
systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris
(other than oralretinoids, which require a 6-month washout), or 5) systemic anti-
inflammatory agents.

10. Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2)
topical retinoids, 3) topical acne treatments including over-the-counter preparations,
4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.

11. Subjects who have had general anesthesia for any reason and patients who have received
neuromuscular blocking agents within 14 days prior to study entry (Randomization).

12. Concomitant use of facial product containing glycolic or other acids, masks, washes or
soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or
moisturizers containing retinol, salicylic or α- or β-hydroxy acids.

13. Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12),
haloperidol, halogens such as iodide and bromide, lithium, hydantoin and
phenobarbital.

14. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2
weeks or during the study.

15. Concomitant use of tanning booths or sunbathing.

16. A significant medical history of or are currently immunocompromised

17. Have any systemic or dermatologic disease that may affect the evaluation of study
results.

18. Have a history of regional enteritis, ulcerative colitis, pseudomembranous colitis or
antibiotic-associated colitis.

19. Subjects with clinically significant unstable medical disorders, life-threatening
disease, or current malignancies.